Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma

Mary Maluccio, Anne Covey

Research output: Contribution to journalArticle

496 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over several years. As such, there has been a focus on safe and accurate diagnosis and the development of treatment algorithms that take into consideration the unique complexities of this patient population. In the past decade, there have been improvements in nonsurgical treatment platforms and better standardization with respect to the diagnosis and patient eligibility for liver transplant. How to navigate patients through the challenges of treatment is difficult and depends on several factors: 1) patient-related variables such as comorbid conditions that influence treatment eligibility; 2) liver-related variables such as Child-Pugh score; and 3) tumor-related variables such as size, number, pattern of spread within the liver, and vascular involvement. The objectives of this review are to put into perspective the current treatment options for patients with HCC, the unique advantages and disadvantages of each treatment approach, and the evidence that supports the introduction of sorafenib into the multidisciplinary management of HCC. CA Cancer J Clin 2012;. © 2012 American Cancer Society.

Original languageEnglish
Pages (from-to)394-399
Number of pages6
JournalCa-A Cancer Journal for Clinicians
Volume62
Issue number6
DOIs
StatePublished - Nov 2012

Fingerprint

Hepatocellular Carcinoma
Liver
Therapeutics
Neoplasms
Blood Vessels
Transplants
Incidence
Population

Keywords

  • decision-making/patient preferences
  • liver neoplasms

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. / Maluccio, Mary; Covey, Anne.

In: Ca-A Cancer Journal for Clinicians, Vol. 62, No. 6, 11.2012, p. 394-399.

Research output: Contribution to journalArticle

@article{cf218af7b58345ec96b373902be399a3,
title = "Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over several years. As such, there has been a focus on safe and accurate diagnosis and the development of treatment algorithms that take into consideration the unique complexities of this patient population. In the past decade, there have been improvements in nonsurgical treatment platforms and better standardization with respect to the diagnosis and patient eligibility for liver transplant. How to navigate patients through the challenges of treatment is difficult and depends on several factors: 1) patient-related variables such as comorbid conditions that influence treatment eligibility; 2) liver-related variables such as Child-Pugh score; and 3) tumor-related variables such as size, number, pattern of spread within the liver, and vascular involvement. The objectives of this review are to put into perspective the current treatment options for patients with HCC, the unique advantages and disadvantages of each treatment approach, and the evidence that supports the introduction of sorafenib into the multidisciplinary management of HCC. CA Cancer J Clin 2012;. {\circledC} 2012 American Cancer Society.",
keywords = "decision-making/patient preferences, liver neoplasms",
author = "Mary Maluccio and Anne Covey",
year = "2012",
month = "11",
doi = "10.3322/caac.21161",
language = "English",
volume = "62",
pages = "394--399",
journal = "Ca-A Cancer Journal for Clinicians",
issn = "0007-9235",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma

AU - Maluccio, Mary

AU - Covey, Anne

PY - 2012/11

Y1 - 2012/11

N2 - Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over several years. As such, there has been a focus on safe and accurate diagnosis and the development of treatment algorithms that take into consideration the unique complexities of this patient population. In the past decade, there have been improvements in nonsurgical treatment platforms and better standardization with respect to the diagnosis and patient eligibility for liver transplant. How to navigate patients through the challenges of treatment is difficult and depends on several factors: 1) patient-related variables such as comorbid conditions that influence treatment eligibility; 2) liver-related variables such as Child-Pugh score; and 3) tumor-related variables such as size, number, pattern of spread within the liver, and vascular involvement. The objectives of this review are to put into perspective the current treatment options for patients with HCC, the unique advantages and disadvantages of each treatment approach, and the evidence that supports the introduction of sorafenib into the multidisciplinary management of HCC. CA Cancer J Clin 2012;. © 2012 American Cancer Society.

AB - Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over several years. As such, there has been a focus on safe and accurate diagnosis and the development of treatment algorithms that take into consideration the unique complexities of this patient population. In the past decade, there have been improvements in nonsurgical treatment platforms and better standardization with respect to the diagnosis and patient eligibility for liver transplant. How to navigate patients through the challenges of treatment is difficult and depends on several factors: 1) patient-related variables such as comorbid conditions that influence treatment eligibility; 2) liver-related variables such as Child-Pugh score; and 3) tumor-related variables such as size, number, pattern of spread within the liver, and vascular involvement. The objectives of this review are to put into perspective the current treatment options for patients with HCC, the unique advantages and disadvantages of each treatment approach, and the evidence that supports the introduction of sorafenib into the multidisciplinary management of HCC. CA Cancer J Clin 2012;. © 2012 American Cancer Society.

KW - decision-making/patient preferences

KW - liver neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84869475394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869475394&partnerID=8YFLogxK

U2 - 10.3322/caac.21161

DO - 10.3322/caac.21161

M3 - Article

C2 - 23070690

AN - SCOPUS:84869475394

VL - 62

SP - 394

EP - 399

JO - Ca-A Cancer Journal for Clinicians

JF - Ca-A Cancer Journal for Clinicians

SN - 0007-9235

IS - 6

ER -